Novartis Pretax Profit Margin from 2010 to 2025

NVS Stock  USD 112.13  1.08  0.95%   
Novartis Pretax Profit Margin yearly trend continues to be comparatively stable with very little volatility. Pretax Profit Margin will likely drop to 0.25 in 2025. From the period from 2010 to 2025, Novartis Pretax Profit Margin quarterly data regression had r-value of  0.26 and coefficient of variation of  36.65. View All Fundamentals
 
Pretax Profit Margin  
First Reported
2010-12-31
Previous Quarter
0.26371757
Current Value
0.25
Quarterly Volatility
0.08120831
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novartis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novartis' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 B, Interest Expense of 571.2 M or Selling General Administrative of 7.3 B, as well as many indicators such as Price To Sales Ratio of 2.76, Dividend Yield of 0.0247 or PTB Ratio of 2.35. Novartis financial statements analysis is a perfect complement when working with Novartis Valuation or Volatility modules.
  
Check out the analysis of Novartis Correlation against competitors.

Latest Novartis' Pretax Profit Margin Growth Pattern

Below is the plot of the Pretax Profit Margin of Novartis AG ADR over the last few years. It is Novartis' Pretax Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novartis' overall financial position and show how it may be relating to other accounts over time.
Pretax Profit Margin10 Years Trend
Pretty Stable
   Pretax Profit Margin   
       Timeline  

Novartis Pretax Profit Margin Regression Statistics

Arithmetic Mean0.22
Geometric Mean0.21
Coefficient Of Variation36.65
Mean Deviation0.05
Median0.20
Standard Deviation0.08
Sample Variance0.01
Range0.3362
R-Value0.26
Mean Square Error0.01
R-Squared0.07
Significance0.32
Slope0
Total Sum of Squares0.1

Novartis Pretax Profit Margin History

2021 0.49
2018 0.26
2015 0.16
2014 0.23
2012 0.2
2011 0.18
2010 0.25

About Novartis Financial Statements

Novartis shareholders use historical fundamental indicators, such as Pretax Profit Margin, to determine how well the company is positioned to perform in the future. Although Novartis investors may analyze each financial statement separately, they are all interrelated. The changes in Novartis' assets and liabilities, for example, are also reflected in the revenues and expenses on on Novartis' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Pretax Profit Margin 0.26  0.25 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.